Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer
Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer
To investigate of the clinical safety and effectiveness of eribulin mesylate in patients with inoperable or recurrent breast cancer
Inclusion criteria :
Exclusion criteria :
Minamisoma, Fukushima, Japan
Aki, Hiroshima, Japan
Higashiibaraki, Ibaraki, Japan
Yamatotakada, Nara, Japan
Nakagami, Okinawa, Japan
Hiki, Saitama, Japan
Sunto, Shizuoka, Japan
Bunkyo, Tokyo, Japan
Koto, Tokyo, Japan
Shinagawa, Tokyo, Japan
Nakaniikawa, Toyama, Japan
Minamikoma, Yamanashi, Japan